

Direct Oral Anticoagulant (DOAC) Guideline

Background

Apixaban, dabigatran, edoxaban and rivaroxaban are all approved by NICE for stroke prevention in non-valvular atrial fibrillation. Apixaban is the first DOAC to come off patent and, as such, is currently the most cost-effective option.

Increasing the use of apixaban in place of the other DOACs will release substantial savings which can be reinvested in identifying and treating additional patients with atrial fibrillation (AF).

The One Gloucestershire Medicines Optimisation Group supports the promotion of apixaban and has provided the following guidance for prescribers:

Indication for Anticoagulation	DOAC of choice
Venous Thromboembolism (VTE) Treatment	
Acute treatment of VTE	Apixaban or rivaroxaban
Cancer-associated thrombosis	Apixaban
Non-valvular AF / flutter	
First line	Apixaban
Second line	Rivaroxaban Edoxaban Dabigatran
Other conditions	
High-risk acute coronary syndrome (in combination with aspirin +/- clopidogrel)	Rivaroxaban 2.5mg bd (Consultant Cardiologist initiation only)
Combined coronary artery disease / peripheral artery disease (CAD/PAD) – in combination with aspirin	Rivaroxaban 2.5mg bd
VTE prophylaxis following orthopaedic surgery	Apixaban , rivaroxaban, or dabigatran
Moderate to severe mitral stenosis	DOAC not suitable
Mechanical prosthetic heart valve	DOAC not suitable
Antiphospholipid syndrome	DOAC not suitable

Apixaban Dosing Information for Non-valvular AF / flutter

Apixaban 5mg bd

Reduce to 2.5mg bd if:

- CrCl < 30 mls/min (apixaban not recommended if CrCl < 15 mls/min)

Or:

- In combination with dual antiplatelet therapy (DAPT) – full dose may be used with single antiplatelet

Or:

- 2 or more of the following apply:
 - Age 80 years or over
 - body weight ≤60kg
 - serum creatinine ≥133 micromol/litre

Non-valvular AF Definition: AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate to severe mitral stenosis (usually of rheumatic origin).

Additional Notes

When switching to apixaban from a different anticoagulant, please refer to the [switching guideline](#) for timings.

Acute Treatment of VTE

When used to treat VTE, edoxaban and dabigatran must be preceded by 5 days of 'treatment dose' low molecular weight heparin (LMWH).[1,2] Apixaban and rivaroxaban do not require prior LMWH treatment[3,4] and are therefore preferred for acute treatment.

Cancer-Associated Thrombosis (CAT)

In the CARAVAGGIO study, apixaban was shown to be non-inferior to LMWH for CAT and had a similar rate of bleeding.[5] In the Hokusai VTE Cancer study, edoxaban was non-inferior to LMWH but the rate of major bleeding was higher.[6]

Previous or High Risk of GI Bleeding

The RE-LY trial demonstrated that dabigatran 110mg bd showed superiority over warfarin for overall major bleeding. However, both doses of dabigatran (150mg and 110mg) had a higher incidence of major GI bleeding in comparison to warfarin.[7] In addition, dabigatran capsules contain tartaric acid, which can contribute to dyspepsia and are therefore best avoided in patients with GI disorders.[2]

In the ROCKET-AF trial there was no significant difference in major bleeding, fewer fatal bleeds but more GI bleeds with rivaroxaban compared with warfarin.[8] Dyspepsia is an established side effect of rivaroxaban, therefore should be used with caution in patients with GI disease even without active ulceration.[4]

The ARISTOTLE trial demonstrated a lower risk of overall major bleeding with apixaban versus warfarin and a comparable rate of GI bleeding.[9]

The ENGAGE-AF TIMI 48 study demonstrated a lower risk of overall major bleeding with edoxaban versus warfarin but an increased risk of GI bleeding with edoxaban 60mg versus warfarin.[10]

The prescribing of an anticoagulant for patients with a high GI bleed risk score should be based on consideration of any options to reduce bleed risk factors, the individual patient's stroke risk and shared patient decision making.

Concomitant Antiplatelet Treatment

Concomitant antiplatelet treatment with all oral anticoagulants increases patients' risk of bleeding; however, combination therapy may be required in patients with a need for anticoagulation (e.g. NVAf) and ischaemic heart disease – notably acute coronary syndrome or those treated with percutaneous coronary intervention (PCI).

General Recommendations:

- Clopidogrel is the P₂Y₁₂ inhibitor of choice (avoid prasugrel or ticagrelor in combination with a DOAC)
- The treatment plan (i.e. antiplatelet durations) should be clearly communicated in the Discharge Summary
- Prescribe a proton-pump inhibitor (e.g. lansoprazole) for gastroprotection when a DOAC is prescribed in combination with antiplatelet(s). Avoid combining omeprazole or esomeprazole with clopidogrel.
- DOAC dosing with concomitant antiplatelet(s) [11-15]:

DOAC	Max. dose with concomitant dual antiplatelet therapy (DAPT) e.g. DOAC + aspirin + clopidogrel	Max. dose with concomitant single antiplatelet therapy e.g. DOAC + clopidogrel
Apixaban	2.5mg BD	5mg BD
Dabigatran	110mg BD	110mg BD
Edoxaban	30mg OD	30mg OD
Rivaroxaban	15mg OD	15mg OD

In the absence of definitive evidence showing the best antiplatelet/anticoagulation regimen for patients with AF undergoing PCI, the European Cardiology Society makes the following recommendations[15]:

Please note that these recommendations are a guide. The antiplatelet/anticoagulation regimen will be individualised by the Interventional Cardiologist.

Low risk of stent thrombosis (or concerns about bleeding risk prevail over risk of stent thrombosis):

- Triple therapy (aspirin + clopidogrel + DOAC) for ≤ 1 week, followed by
- Dual therapy (clopidogrel + DOAC) for up to 6 months (in chronic coronary syndrome) or up to 12 months (in acute coronary syndrome), followed by
- DOAC monotherapy

Risk of stent thrombosis outweighs bleeding risk:

- Triple therapy (aspirin + clopidogrel + DOAC) for ≤ 1 month, followed by
- Dual therapy (clopidogrel + DOAC) for up to 6 months (in chronic coronary syndrome) or up to 12 months (in acute coronary syndrome), followed by
- DOAC monotherapy

Renal Impairment

It is essential to calculate patients' creatinine clearance (CrCl) using the Cockcroft-Gault equation (use actual body weight) before DOAC initiation and annually thereafter. Estimated glomerular filtration rate (eGFR) can overestimate renal function and increase the risk of bleeding events (see [Drug Safety Update](#)). There is risk of DOAC accumulation and subsequent bleeding in renal impairment. Dose reductions are recommended in mild-moderate renal impairment, refer to individual SPCs for dosing advice. Dose adjustment may be necessary if renal function significantly changes during treatment. All DOACs are unlicensed in severe renal impairment CrCl <15 ml/min (with the exception of dabigatran which should be avoided in CrCl <30 ml/min). Consider discussion with renal team if CrCl <15 .

Obesity

The International Society on Thrombosis and Haemostasis recommends that standard doses of rivaroxaban or apixaban are among appropriate anticoagulant options regardless of high BMI and weight. Fewer supportive data exist for apixaban than rivaroxaban.[16]

References:

1. Summary of Product Characteristics, Lixiana 60mg film-coated tablets. Electronic Medicines Compendium. Last updated on emc: 12 January 2021 [accessed 08/02/22] www.medicines.org.uk
2. Summary of Product Characteristics, Pradaxa 150mg hard capsules. Electronic Medicines Compendium. Last updated on emc: 11 January 2022 [accessed 08/02/22] www.medicines.org.uk
3. Summary of Product Characteristics, Eliquis 5mg film-coated tablets. Electronic Medicines Compendium. Last updated on emc: 28 May 2021 [accessed 08/02/22] www.medicines.org.uk
4. Summary of Product Characteristics, Xarelto 20mg film-coated tablets. Electronic Medicines Compendium. Last updated on emc: 17 January 2022 [accessed 08/02/22] www.medicines.org.uk
5. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. *N Engl J Med*. 2020;382:1599-1607
6. Van Es N, Di Nisio M, Bleker S, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thromb Haemost*. 2015; 114(6):1268-76
7. Connolly SJ, Ezekowitz et al. Dabigatran versus warfarin in patients with atrial fibrillation (RELY). *N Engl J Med*. 2009;361(12):1139-1151.

8. Patel MR, Mahaffey KW et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET-AF). *N Engl J Med*. 2011;365(10):883-891.
9. Grangers CB, Alexander JH et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). *N Engl J Med*. 2011; 365(11):981-992.
10. Giugliano RP, Ruff CT et al. Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE-AF TIMI 48). *N Engl J Med* 2013; 369: 2093-2104.
11. Gibson M, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N Engl J Med* 2016; 375:2423-2434
12. Cannon C, Bhatt D, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N Engl J Med* 2017; 377:1513-1524
13. Lopes R, Heizer G, Aronson R, et al. Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation – AUGUSTUS. *N Engl J Med* 2019; 380:1509-1524
14. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet* 2019;394:1335-1343
15. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *European Heart Journal* 2021;42(5):373-498
16. Martin, K.A., Beyer-Westendorf, J., Davidson, B.L., et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *J. Thromb. Haemost.* 2021;119: 1874-1882